- Home
- AMST vs SABS Comparison
AMST vs SABS Comparison
Compare AMST & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- SABS
- Stock Information
- Founded
- AMST 2017
- SABS 2014
- Country
- AMST United States
- SABS United States
- Employees
- AMST N/A
- SABS N/A
- Industry
- AMST Computer Software: Prepackaged Software
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- AMST Technology
- SABS Health Care
- Exchange
- AMST Nasdaq
- SABS Nasdaq
- Market Cap
- AMST 13.3M
- SABS 15.8M
- IPO Year
- AMST 2020
- SABS N/A
- Fundamental
- Price
- AMST $2.74
- SABS $2.28
- Analyst Decision
- AMST
- SABS Strong Buy
- Analyst Count
- AMST 0
- SABS 5
- Target Price
- AMST N/A
- SABS $10.00
- AVG Volume (30 Days)
- AMST 14.0K
- SABS 85.9K
- Earning Date
- AMST 09-29-2025
- SABS 11-05-2025
- Dividend Yield
- AMST N/A
- SABS N/A
- EPS Growth
- AMST N/A
- SABS N/A
- EPS
- AMST N/A
- SABS N/A
- Revenue
- AMST $82,544.00
- SABS $114,698.00
- Revenue This Year
- AMST N/A
- SABS N/A
- Revenue Next Year
- AMST N/A
- SABS N/A
- P/E Ratio
- AMST N/A
- SABS N/A
- Revenue Growth
- AMST N/A
- SABS N/A
- 52 Week Low
- AMST $2.00
- SABS $1.00
- 52 Week High
- AMST $6.27
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- AMST 47.08
- SABS 54.42
- Support Level
- AMST $2.63
- SABS $2.03
- Resistance Level
- AMST $2.83
- SABS $2.34
- Average True Range (ATR)
- AMST 0.13
- SABS 0.12
- MACD
- AMST 0.01
- SABS 0.02
- Stochastic Oscillator
- AMST 53.85
- SABS 84.00
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.